FDA Brief

Warning letters Drugs

FDA warning letter to

Right Value Drug Stores, LLC dba Carie Boyd Pharmaceuticals

High riskIssued Dec 17, 2024Posted Mar 11, 2025Center for Drug Evaluation and Research (CDER)

FDA warned outsourcing facility Carie Boyd Pharmaceuticals in Irving, TX that sterile drug production had airflow, media fill and contamination control failures.

What happened

FDA inspected the facility from May 28 to June 21, 2024 and issued a Form FDA 483 listing problems on the last day. Investigators found smoke studies that did not show unidirectional airflow in a biological safety cabinet, media fills that did not mimic worst-case production, and container closures used after depyrogenation (removal of fever-causing residue) failed endotoxin testing without the validation being repeated. FDA reviewed the company's July 15, 2024 response and found several corrective actions inadequate or undocumented.

What FDA found

  1. Smoke studies did not show unidirectional airflow in the ISO 5 hood, so sterile products may be exposed to contamination.

    FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  2. Media fills (test runs using growth medium instead of drug) were not run under the most challenging conditions, so there is no assurance the firm can fill sterile products safely.

    FDCA § 501(a)(2)(A) [21 U.S.C. § 351(a)(2)(A)]
  3. The firm did not follow adequate written procedures to prevent microbiological contamination, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  4. The firm did not thoroughly investigate unexplained batch failures, including 26 vials with dark particulates and filaments found during visual inspection.

    21 CFR 211.192
  5. The firm did not properly clean and sterilize vial caps to remove pyrogens (fever-causing residue), and the failed validation was never repeated.

    21 CFR 211.94(c)
  6. Labels on several compounded drugs did not state the quantity or proportion of each inactive ingredient.

    FDCA § 503B(a)(10) [21 U.S.C. § 353b(a)(10)]

What FDA wants

Within 15 working days, the company must write to FDA describing each corrective step, how it will prevent recurrence, and supporting documentation, or explain why it needs more time. FDA also strongly recommends a comprehensive third-party assessment of the facility's aseptic processing operations.

Who should pay attention

  • hospitals, clinics and patients that buy compounded sterile injections from outsourcing facilities
  • pharmacies and prescribers sourcing testosterone or ketoconazole compounds from this facility
  • other 503B outsourcing facilities with similar smoke study, media fill or depyrogenation programs

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk